European Archives - Page 518 of 1129 - European Medical Journal

Bridging the digital health divide

Technology has redefined the exchange of health information. Find out how the pharma industry can help patients build confidence about digital health tools.

Curious Case of SGLT2 Inhibitor: From the Apple Tree to Shifting Paradigm

James Kim is a general practitioner with a special interest in chronic diseases, especially diabetes and chronic migraine. He is…

Trading Song For Science

This week, Jonathan is joined by Mike Einziger, a multiple Grammy-nominated musician, inventor, and technology entrepreneur.

Cardiovascular Autonomic Neuropathy May Predict Complications in Type 2 Diabetes

Cardiovascular autonomic neuropathy (CAN) might be a useful marker for long-term complications in patients with Type 2 diabetes (T2D)…

Artificial Pancreas App for Children with Type 1 Diabetes

An Android app has been created to manage insulin delivery in very young children affected by Type 1 diabetes…

Nurturing home-grown innovation in Europe

Europe is a front runner for pharmaceutical research and thought leadership Find out in what measure this is translating into home-grown innovation.

Sanofi and GSK seek COVID-19 vaccine approval

Sanofi and GSK are seeking regulatory approval for their adjuvanted protein-based COVID-19 vaccine, as a primary two-dose series and booster dose.

EMJ Oncology 10 [Supplement 4] 2022 Feature Image

Evolving the Role for Immunotherapy in Lung Cancer: Extensive-Stage Small Cell Lung Cancer and Unresectable Stage III Non-small Cell Lung Cancer

Lung cancer is classified into NSCLC (85% of patients) and SCLC (15%). NSCLC can be further classified histologically into three main type…

EMJ Oncology 10 [Supplement 4] 2022 Feature Image

EMJ Oncology 10 [Supplement 4] 2022

Expert discussion on the evolving role of immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) from symposium sessions at the virtual 2020 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer are reviewed in this article. Masahiro Tsuboi, National Cancer Centre Hospital East, Tokyo, Japan, chaired and opened the session by exploring the role of immuno-oncology in the management of unresectable Stage III non-small cell lung cancer (NSCLC).

Reacting to supply chain risks

The pharmaceutical supply chain is vulnerable to adverse events, and the pandemic has served as a reminder of how these networks can be tested. The industry has learned tough lessons from COVID-19 that must be translated into modernisation and improvements